Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
In March I observed that “I’m still not buying the stock – or drinking the product – of Fevertree (FEVR)” HERE. The one line view is that nothing has changed and (interestingly given the general market movements over the last few months) the share price is about the same level as it was about six months ago. Whilst the latter sounds dull – especially as the dividend yield is still under 1% – it has not been a disaster given the volatility in some other share prices. The challenge for Fever-Tree however remains its c. x40 EV:EBIT multiple for the full year, around double the level of underlying operating earnings growth. As always, it depends on what you pay for forward growth potential.
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen